Von Eschenbach nomination blocked again

Share this article:
Sen. Charles Grassley (R-Iowa) said he would block Andrew von Eschenbach’s confirmation to head the FDA. As a reason for his opposition, Grassley cited von Eschenbach’s failure to comply with subpoenas issued by the Senate Finance Committee, which has oversight over the FDA. In a letter to outgoing Majority Leader Bill Frist (R-Tenn.), Grassley also mentioned that he and Sen. Max Baucus (D-Mont.) had met with HHS Secretary Mike Leavitt to express their objections. Grassley asked Frist to consult him before “entering into any unanimous consent agreement” on von Eschenbach’s nomination, according to Bloomberg News. The letter didn’t describe the subject of the subpoenas, issued in May for access to documents and an agency employee. Grassley’s represents the third hold on the von Eschenbach nomination by a Republican senator. The other two Republican holds have come from Sens. Jim DeMint of South Carolina and David Vitter of Louisiana. DeMint wants the FDA to withdraw abortion drug RU- 486 from the market, while Vitter is trying to get the Bush administration to allow some prescription drug imports. Before DeMint and Vitter moved to block the nomination, Democrats were holding it up over Barr Pharmaceuticals’ application to sell the Plan B contraceptive without a prescription. The FDA cleared the over-the-counter sales in August for women ages 18 and older.
Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...